How to Sequence HCP Media Across Display, Video, and Professional Channels
A state-based approach to sequencing HCP media, giving each channel a clear job and an observable signal instead of a rigid funnel.
The short answer
HCP media sequencing is the plan for which channel reaches a prescriber first, what follows, and what triggers the next step. The traditional approach assigns channels to funnel stages: video for awareness, display for consideration, email for action. Real prescribers do not follow that path. A better approach defines prescriber states, gives each channel a job, and moves budget based on signals you can observe.
Define the states
Keep the number of states small enough to act on:
- Not yet reached. On the target list, no verified exposure yet.
- Reached. Verified exposure, no engagement signal.
- Engaged. Took an action: site visit, content view, video completion above a threshold.
- Active interest. Deeper action: sample or rep request, repeated visits, resource download.
Each state has an entry signal that you can measure at the NPI level or, where privacy rules require it, in aggregate.
Assign each channel a job
| Channel | Typical job | Observable signal |
|---|---|---|
| Programmatic display to NPI list | Efficient reach and repetition | Verified list reach and frequency |
| Online video and HCP CTV | Explain a clinical concept with depth | Completion and time viewed |
| Endemic sites and point-of-care | Reach in a professional context | Placement engagement |
| Email and professional portals | Deliver detail to engaged prescribers | Opens, clicks, content downloads |
| Field and inside sales | Handle questions and access issues | Rep activity logs |
The same channel can do different jobs for different brands. What matters is that the job is written down and tied to a signal.
Sequencing rules
A sequencing rule says what happens when a prescriber enters a state. For example:
- Reached but not engaged after a set frequency: reduce display frequency and try a different channel or message.
- Engaged: shift to deeper content channels and suppress broad reach impressions.
- Active interest: trigger field or inside sales follow-up if your data agreements allow it.
Rules like these require data to flow between partners. Check what your contracts and privacy policies permit before designing them. Some sequencing can only be done in aggregate.
Compliance in sequenced journeys
Every piece of promotional content in the sequence must present risk information appropriately for its format. Shorter or reminder formats have specific constraints. The FDA's guidance on presenting risk information is a useful planning reference. Plan the sequence with your review team early, since approval timelines limit how many message variants you can use.
Measure the sequence, not just the channels
Channel-level reports hide sequencing effects. Report state transitions too: how many prescribers moved from reached to engaged, and through which channel path. Treat these as associative signals. To know whether the sequence changes prescribing, you still need an outcome study with a comparison group. See HCP engagement metrics for what each signal can support.
Hypothetical example
A brand finds that 60% of reached prescribers never engage after eight display impressions, while those who complete a two-minute video are three times more likely to visit the HCP site. The team caps display at six impressions, adds a video retargeting step for prescribers with partial completions, and moves email to prescribers who have visited the site. All figures are illustrative.
Practical takeaway
Replace the funnel diagram in your plan with a state table: each state, its entry signal, the channels that act on it, and the rule that moves budget. It will be simpler to optimize and easier to explain.
Sources
- FDA, Presenting Risk Information in Prescription Drug and Medical Device Promotion
- Media Rating Council, Standards and Guidelines
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.